Hangzhou Alltest Biotech Co., Ltd. (688606.SS)
CNY 67.04
(0.43%)
CNY 67.04
(0.43%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 249.76 Million CNY | -89.45% |
| 2022 | 1.41 Billion CNY | 92.41% |
| 2021 | 915.17 Million CNY | 7.03% |
| 2020 | 829.94 Million CNY | 888.77% |
| 2019 | 92.87 Million CNY | 19.61% |
| 2018 | 66.01 Million CNY | 68.83% |
| 2017 | 40.44 Million CNY | 139.55% |
| 2016 | 19.1 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 84.27 Million CNY | 7.7% |
| 2024 Q1 | 60.74 Million CNY | -50.17% |
| 2024 Q2 | 78.25 Million CNY | 65.47% |
| 2023 Q3 | 49.94 Million CNY | 311.6% |
| 2023 FY | - CNY | -89.45% |
| 2023 Q4 | 40.6 Million CNY | -18.69% |
| 2023 Q2 | 12.13 Million CNY | -80.64% |
| 2023 Q1 | 62.68 Million CNY | 19.85% |
| 2022 FY | - CNY | 92.41% |
| 2022 Q3 | 31.24 Million CNY | -89.43% |
| 2022 Q2 | 295.57 Million CNY | -77.49% |
| 2022 Q1 | 1.31 Billion CNY | 274.19% |
| 2022 Q4 | 52.3 Million CNY | 67.39% |
| 2021 Q1 | 176.75 Million CNY | -54.02% |
| 2021 Q4 | 350.89 Million CNY | 143.07% |
| 2021 Q3 | 144.35 Million CNY | -34.93% |
| 2021 Q2 | 221.85 Million CNY | 25.52% |
| 2021 FY | - CNY | 7.03% |
| 2020 Q4 | 384.38 Million CNY | 410.88% |
| 2020 Q3 | 75.23 Million CNY | -78.62% |
| 2020 Q2 | 351.92 Million CNY | 870.07% |
| 2020 Q1 | 36.27 Million CNY | 110.79% |
| 2020 FY | - CNY | 888.77% |
| 2019 Q4 | 17.21 Million CNY | 0.0% |
| 2019 FY | - CNY | 19.61% |
| 2018 FY | - CNY | 68.83% |
| 2017 FY | - CNY | 139.55% |
| 2016 FY | - CNY | 0.0% |